European Archives - Page 759 of 1117 - European Medical Journal

EMJ Oncology 6 [Suppl 2] 2018

These valuable insights were obtained from a series of interviews conducted between 19th September and 8th October 2018 by the European Medical Journal…

Innovate to elevate HCP engagement

The regulatory ecosystem of the pharmaceutical industry and people’s decreasing attention spans is proving a complex reality for marketers that has provided an imperative to innovate.

Adherence: a bespoke regime

What helps people to stick to their medication regimes, and how can pharma begin to recover their revenue as well as striving for better health outcomes?

ProbeFix: Continuous Ultrasound Imaging and Improved Ergonomics

Working in the medical sector, whether as a nurse, researcher, or doctor, is often physically demanding. Healthcare workers are reported to sustain…

An Interview with Daniel De Schryver from Janssen

An interview with Daniel De Schryver, Patient Engagement & Advocacy Lead, EMEA, Janssen Pharmaceutical Companies of Johnson & Johnson at the eyeforpharma Patient Summit, Europe. Daniel talks about overcoming fear to create a genuine dialogue that will make better solutions for patients and how his past experiences have helped shape his leadership today.

Focus on Family: Family is the Key for Detection, Prevention, and Management of Diabetes! A World Diabetes Day Message

In 2017, the International Diabetes Federation (IDF)1 reported that 425 million adults have diabetes worldwide, and India alone has 73 million adults…

Screening Programmes Improve Chances of Survival in Breast Cancer Patients

Debate has been ongoing for some time in the medical community as to whether screening programmes for breast cancer have any significant impact on the…

Universal Blood Test for Cancer Under Development

Diagnosing cancer at an early stage is acknowledged as one of the best ways to achieve the best possible outcome for patients. With the incidence of…

An Interview with Asad Mohsin Ali from Ipsen

An interview with Asad Mohsin Ali, General Manager UK and Ireland, Ipsen, who talks about how pharmaceutical companies can add value and why market access is becoming a hot topic.

Positive Phase II Trial Results Assessing Ustekinumab for the Treatment of Systemic Lupus Erythematosus (SLE)

Lupus is a condition for which the creation of new treatment options is of paramount importance. There is as yet no cure for the disease…